Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency

Abstract

Clonotypic B cells are frequently isolated from the peripheral blood of patients with multiple myeloma (MM).[1][1] These clonotypic B cells may be the clonogenic cells of MM. We have hypothesized that rituximab, a chimeric CD20 monoclonal antibody, may be a useful maintenance therapy in MM after